2 July - New PRIME Tools to Accelerate Development of Medicines in the EU: What It Means for Industry and Regulatory Careers

In March 2026, the European Medicines Agency (EMA) made a landmark announcement. After completing a two-year pilot programme, the agency formally launched three major new features under its PRIME (PRIority MEdicines) scheme — powerful tools designed to improve how innovative medicines reach patients across the European Union. For pharmaceutical developers, biotech companies, and the regulatory professionals who support them, this is not a routine administrative update. It represents a structural shift in how the EU regulatory ecosystem operates.

Ten years after PRIME was first introduced in 2016, the scheme has grown into one of the most strategically important accelerated development pathways in global pharma. These new tools — combined with a forthcoming overhaul of EU pharmaceutical legislation that will formally codify PRIME into law — represent the most significant evolution of the scheme since its inception. As the Head of Scientific Evidence Generation at EMA, Michael Berntgen, stated upon the announcement: "Over the ten years since its launch, PRIME has continued to evolve to keep pace with scientific innovation and accelerate the development and assessment of innovative medicines."

What Is the PRIME Scheme — and Why Does It Matter?

The March 2026 Update: Three New PRIME Tools Explained

The EMA Product Development Coordinator: A New Model for Developer Support

The EU Pharmaceutical Legislation Revision: PRIME Gets Legal Status

PRIME vs. FDA Breakthrough Therapy Designation: Understanding the Global Picture

What the New PRIME Tools Mean for Business: A Practical Action Plan

The Career Opportunity: Why PRIME Expertise Is One of the Most Valuable Skills in Regulatory Affairs Right Now

Choosing the Right Training: What the Market Actually Values

Ready to Launch Your Regulatory Affairs Career in the EU and Beyond?

What Is the PRIME Scheme — and Why Does It Matter?

Before examining the new tools in detail, it is worth grounding the discussion in what PRIME actually is and why it has become so important to the pharmaceutical industry.

PRIME — PRIority MEdicines — is the EMA's flagship scheme to enhance support for medicines that target an unmet medical need. Launched in March 2016, it is available to developers whose medicines show early evidence of substantial clinical improvement over existing treatments — particularly in conditions where no satisfactory therapy currently exists, or where current treatments cause significant harm or burden.

The scheme's core purpose is to get transformative medicines to patients faster. It does this by:

- Enabling early and proactive dialogue between developers and the EMA

- Providing tailored scientific guidance through an appointed CHMP (Committee for Medicines for Human Use) rapporteur

- Potentially facilitating accelerated assessment at marketing authorisation stage — reducing the standard 210-day review clock

- Offering enhanced support for small and medium-sized enterprises (SMEs) and academic research groups through an "Early Entry PRIME" status

Who Qualifies for PRIME?

Eligibility for PRIME designation is competitive and selective. In 2024, the EMA received 58 eligibility requests and granted access to just 15 products — a 27% acceptance rate. To qualify, a medicine must:

- Target a condition with a significant unmet medical need, where current treatments are absent, insufficient, or poorly tolerated

- Present preliminary clinical evidence — typically from first-in-human trials — suggesting meaningful therapeutic benefit

- Demonstrate potential to offer patients something substantially better than the status quo

PRIME has proven its real-world value. Data shows that PRIME designation reduces approval timelines for Advanced Therapy Medicinal Products (ATMPs) — including gene therapies, cell therapies, and tissue-engineered products — by nearly one year compared to non-PRIME products. For developers working on rare diseases, oncology, and next-generation biologics, that difference is not just commercial — it is life-saving.

The March 2026 Update: Three New PRIME Tools Explained

On 18 March 2026, following the successful conclusion of a two-year pilot, the EMA permanently integrated three new features into the PRIME scheme. These tools address one of the most persistent and costly challenges in innovative medicine development: the gap between scientific ambition and regulatory readiness.

Tool 1: The Regulatory Roadmap and Product Development Tracker

The first new feature is a structured regulatory roadmap combined with a live product development tracker. This tool allows developers and the EMA to jointly chart a medicine's full development journey from an early stage, creating a shared and continuously updated reference point for both parties.

What it does:

- Establishes a clear, milestone-based development roadmap at the outset of PRIME engagement

- Enables both the developer and the EMA rapporteur to monitor progress in real time

- Flags potential issues early — before they escalate into submission-blocking problems

- Maintains alignment between developers and the EMA throughout what are often complex, multi-year development programmes

Why it matters for industry:

One of the most expensive and avoidable failures in pharmaceutical development is arriving at the marketing authorisation stage with an evidence package that does not meet the EMA's expectations. Rework at that point costs tens of millions of euros and can delay patient access by years. The regulatory roadmap transforms regulatory strategy from a reactive activity into a proactive one — and that shift has enormous commercial value.

The EMA has indicated that future refinements will include digital solutions for real-time product development tracking, signalling a move toward a more technology-enabled regulatory dialogue model.

What it means for regulatory professionals:

This tool introduces a new ongoing engagement model that demands strong project management capability alongside traditional regulatory science expertise. Regulatory affairs professionals working on PRIME programmes will be expected to manage living roadmap documents, coordinate milestone reviews, and anticipate regulatory objections before they materialise.

Tool 2: Expedited Scientific Advice

The second new feature introduces a fast-track route for scientific advice — enabling developers to receive focused, timely regulatory input from the EMA on specific, critical development questions when the stakes are highest.

What it does:

- Provides accelerated access to EMA scientific expertise on targeted questions that are critical to the development programme

- Reduces the waiting time for regulatory input at pivotal decision points — where weeks and months of delay can derail entire programmes

- Is focused on critical path issues, not broad advice: the questions that, if left unresolved, could fundamentally compromise the development strategy

- Is distinct from the standard EMA scientific advice process in both speed and scope of focus

Why it matters for industry:

Under the standard scientific advice model, waiting times for EMA feedback can extend to several months. For developers operating under clinical trial deadlines, this lag can force go/no-go decisions without adequate regulatory input — often resulting in costly redesigns later. Expedited scientific advice eliminates that bottleneck for PRIME-designated products, enabling faster, better-informed development decisions.

Planned refinements include more agile procedures and more flexible meeting scheduling, recognising that development timelines are rarely aligned with administrative calendars.

What it means for regulatory professionals:

This tool places a premium on regulatory professionals who can formulate precise, high-quality scientific advice requests — knowing which questions to ask, how to frame them, and when in the development cycle to escalate. It is a skill that differentiates strong regulatory strategists from pure submission managers.

Tool 3: The Submission Readiness Meeting

The third new feature is a dedicated pre-submission assessment meeting, conducted approximately one year before the anticipated marketing authorisation application (MAA) submission date.

What it does:

- Provides a structured forum in which the developer and EMA jointly assess whether the evidence package is on track to support a comprehensive MAA

- Identifies remaining data gaps that must be addressed before submission — with enough time to actually address them

- Reviews programme progress against the regulatory roadmap established at the start of PRIME engagement

- Ensures the CHMP receives a complete, high-quality dossier at submission — reducing the likelihood of clock-stops and major objections during formal review

Why it matters for industry:

Clock-stops — formal pauses in the EMA review clock while the applicant provides additional data — are among the most costly and time-consuming events in the marketing authorisation process. A single major clock-stop can add six months or more to an approval timeline. The submission readiness meeting is a proactive safeguard against this outcome. By surfacing data gaps 12 months before submission, developers have a genuine opportunity to resolve them without losing time.

What it means for regulatory professionals:

This tool requires regulatory teams to conduct rigorous internal evidence gap analyses well before the meeting — essentially running a pre-submission audit of their own data package. This demands structured analytical skills, strong scientific writing capabilities, and the confidence to raise uncomfortable gaps with internal stakeholders in time to act on them.

The EMA Product Development Coordinator: A New Model for Developer Support

Alongside the three new PRIME tools, the EMA is actively exploring an additional structural innovation: the EMA Product Development Coordinator (PDC).

This pilot model — launched in mid-2025 with approximately 20 PRIME designation holders — designates a single, primary EMA contact point for each developer throughout the full development lifecycle. Rather than navigating different EMA departments at different stages, developers would have one continuous, knowledgeable contact who coordinates regulatory support across the entire development journey.

The concept is already being tested in real-world scenarios. Annexon's vonaprument — a PRIME-designated candidate targeting geographic atrophy (dry age-related macular degeneration), currently in Phase 3 trials with results expected in late 2026 — is one of the early participants in the PDC pilot. The treatment has also received FDA Fast Track Designation, illustrating the type of globally-tracked, high-priority innovation the PRIME ecosystem is increasingly built around.

If formalised, the PDC model would represent a fundamental shift in EMA's engagement structure and would create new types of senior regulatory relationship management roles within the industry.

The EU Pharmaceutical Legislation Revision: PRIME Gets Legal Status

Perhaps the most consequential long-term development accompanying the new PRIME tools is the forthcoming reform of EU pharmaceutical legislation.

When the new EU legislative framework comes into force, it will formally codify PRIME within its statutory provisions. This is a landmark change. PRIME currently operates as an EMA administrative scheme — valuable, but not legally mandated. Once embedded in legislation, it will carry the force of EU law, providing:

- Greater legal certainty for developers investing in PRIME-designated programmes

- Standardised EMA commitments around the support offered under the scheme

- Clearer integration with conditional marketing authorisation, accelerated assessment, and other EU regulatory pathways

- Stronger continuity regardless of future administrative changes at the EMA

For regulatory professionals, this legislative embedding means PRIME expertise will transition from a useful specialism to a core competency for anyone working in EU regulatory strategy. It is a shift with direct implications for training, career planning, and workforce development across the industry.

PRIME vs. FDA Breakthrough Therapy Designation: Understanding the Global Picture

For companies developing medicines globally, understanding how PRIME compares to the FDA's equivalent programme is not optional — it is a fundamental component of regulatory strategy. The two programmes share goals but differ meaningfully in approach.

Research published in peer-reviewed literature shows that when developers apply to both agencies for the same product, approximately two-thirds of requests result in concordant outcomes — meaning the EMA and FDA broadly agree on a product's development promise. However, divergent decisions do occur, reflecting genuine differences in evidentiary standards and regulatory philosophy.

For global programmes, pursuing parallel scientific advice from both the EMA and FDA simultaneously is an increasingly essential strategy — and one that requires regulatory professionals to hold fluency in both frameworks simultaneously.

What the New PRIME Tools Mean for Business: A Practical Action Plan

The new tools do not change PRIME eligibility criteria, but they do change what it means to operate effectively within PRIME. Here is what companies and regulatory teams should be doing right now:

✅ Engage the EMA earlier than feels necessary

The regulatory roadmap tool delivers the most value when established in the exploratory clinical phase. Companies that delay EMA engagement until late-stage clinical data is in hand are already behind the curve. Early interaction — even before first-in-human data — positions developers for a stronger PRIME application and a better-structured development plan.

✅ Identify your critical development questions now

The expedited scientific advice tool is only as valuable as the quality of the questions you bring to it. Regulatory teams should be systematically identifying the key development uncertainties — around clinical endpoints, comparator selection, biomarker strategy, or CMC — that need EMA input, and prioritising them for expedited advice requests.

✅ Treat the submission readiness meeting as a formal milestone

The one-year pre-submission check-in should be built into development timelines as an active programme milestone, not a bureaucratic formality. Evidence gap analyses need to begin well in advance of the meeting itself — ideally 18 to 24 months before anticipated submission.

✅ Build cross-functional regulatory literacy

The PRIME tools require collaboration across clinical, medical affairs, CMC, and regulatory functions. Regulatory professionals who can facilitate genuine cross-functional strategic conversations — not just manage their own submission lane — will be the most effective operators in a PRIME environment.

✅ Align PRIME and FDA strategies from day one

For globally developed medicines, delays caused by misaligned EU and US strategies are both common and avoidable. Regulatory teams must understand both frameworks deeply and integrate them into a single, coherent global development strategy from early clinical planning.

The Career Opportunity: Why PRIME Expertise Is One of the Most Valuable Skills in Regulatory Affairs Right Now

The evolution of PRIME is not only a story about medicines — it is a story about people. Specifically, about the professionals who will be needed to navigate this more complex, more collaborative, more strategically demanding regulatory environment.

EU Regulatory Affairs: The Market in 2026

The European regulatory affairs job market is in a period of sustained growth:

- Entry-level EU regulatory affairs roles command €35,000–€50,000; mid-level roles range from €50,000–€70,000; senior and specialist positions regularly exceed €80,000

- Head of Compliance ranks as the second most resilient career in all of Europe in 2026, according to the European Career Outlook Index (ECOI), with a resilience score of 82 out of 100 — driven by low automation exposure, high organisational visibility, and growing regulatory complexity

- Regulatory Affairs Specialist is consistently cited as one of the fastest-growing roles in European life sciences hiring

- The EMA itself is actively expanding, with Regulatory Affairs Officer positions requiring EU pharmaceutical law expertise, scientific writing proficiency, and demonstrated regulatory intelligence capability

The codification of PRIME into EU law, combined with the new tools requiring deeper and more continuous developer-EMA engagement, is directly driving demand for professionals with specialist EU regulatory expertise. Companies working on PRIME-designated programmes need regulatory professionals who can:

- Build and manage structured regulatory roadmaps

- Navigate EMA scientific advice procedures — including the new expedited route

- Prepare and present evidence gap analyses for submission readiness reviews

- Coordinate across global development programmes involving both EMA and FDA simultaneous engagement

- Communicate regulatory strategy clearly to non-regulatory stakeholders, including C-suite, investors, and clinical leads

Choosing the Right Training: What the Market Actually Values

The regulatory affairs training market has expanded considerably. But the quality and career impact of available options varies dramatically — and in 2026, employers are increasingly specific about what they want to see from candidates.

The pattern in 2026 hiring is consistent and well-documented: employers want real regulatory exposure, not just qualifications. Hiring managers in the regulatory affairs community are explicit — they want to see candidates who have worked on actual submissions, labelling documents, Health Authority communications, or dossier support. That work experience cannot be replicated by online quizzes or academic assignments.

Programmes that bundle regulatory knowledge with hands-on, practical regulatory work experience — the kind that mirrors what employers actually need — are structurally positioned to produce job-ready graduates in a way that self-paced courses simply cannot match.

Key Takeaways: What You Need to Know and Do

Whether you are a pharmaceutical company, a regulatory consultant, or someone planning a career in regulatory affairs, here is your 2026 action plan:

For industry:

- ✅ Review your development pipeline for PRIME eligibility — particularly any ATMPs, rare disease candidates, or first-in-class mechanisms

- ✅ Integrate the regulatory roadmap tool into development planning from the exploratory clinical stage

- ✅ Build expedited scientific advice requests into your critical path planning

- ✅ Schedule submission readiness assessments 12–18 months before your anticipated MAA submission

- ✅ Align your PRIME and FDA Breakthrough Therapy strategies into a single global regulatory framework

For aspiring regulatory professionals:

- ✅ Prioritise EU regulatory training — PRIME expertise is becoming a baseline expectation for European regulatory roles

- ✅ Seek training that includes practical, hands-on regulatory document experience

- ✅ Develop dual-market fluency in both EMA and FDA frameworks — global regulatory strategy is a premium skill

- ✅ Enter the market now — demand for skilled EU regulatory professionals is outpacing supply

Ready to Launch Your Regulatory Affairs Career in the EU and Beyond?

The evolution of PRIME, the reform of EU pharmaceutical legislation, and the growing complexity of global regulatory strategy are creating a genuine talent gap — and a genuine opportunity for people who move now.

At Entry to Regulatory, we provide training courses for anyone trying to build a career in Regulatory Affairs — no previous experience required. Our programme is designed specifically to give you what employers are actually asking for in 2026: real knowledge, real document experience, and real career support.

Here is what you get when you train with us:

- 📋 50+ CPD hours covering EU, US, and UK regulatory frameworks — including the regulations and guidance that are shaping the industry right now

- 🔬 Real-life work assignments — the hands-on regulatory document experience that hiring managers specifically ask for

- 🧑‍💼 Job search support — including CV reviews, mock interviews, and dedicated career mentoring

- 🌐 A professional community of peers, graduates, and industry connections

- 🏆 Proven results — graduates report landing roles within weeks to months, with UK associates earning upwards of £50,000 and US roles offering $100,000+

Whether you are a career-changer, a life sciences graduate, or a professional looking to move into one of the most resilient and well-paid sectors in Europe and beyond — we can help.

Next cohort starts: 12 July 2026. Limited spaces available. 

About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.